Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial

Am J Hematol. 2025 Dec;100(12):2436-2441. doi: 10.1002/ajh.70091. Epub 2025 Oct 2.

Abstract

Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents; IC, intensive chemotherapy.

Keywords: DELTA; elderly AML; eltrombopag; hypomethylating therapy; thrombocytopenia.

Publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase II
  • Multicenter Study
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Azacitidine / administration & dosage
  • Azacitidine / analogs & derivatives
  • Azacitidine / therapeutic use
  • Benzoates* / administration & dosage
  • Benzoates* / adverse effects
  • Benzoates* / therapeutic use
  • Decitabine / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Hydrazines* / administration & dosage
  • Hydrazines* / adverse effects
  • Hydrazines* / therapeutic use
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / mortality
  • Male
  • Middle Aged
  • Pyrazoles* / administration & dosage
  • Pyrazoles* / adverse effects
  • Pyrazoles* / therapeutic use

Substances

  • eltrombopag
  • Hydrazines
  • Pyrazoles
  • Benzoates
  • Azacitidine
  • Decitabine